Literature DB >> 9688016

Four-year trends in Helicobacter pylori IgG serology following successful eradication.

A F Cutler1, V M Prasad, P Santogade.   

Abstract

PURPOSE: Detection of anti-Helicobacter pylori antibodies is accurate in the diagnosis of the infection, and there is a decline in IgG titers after successful eradication. It is not known whether these titers continue to decline during the next 3 to 4 years. PATIENTS AND METHODS: Patients had been successfully treated for H pylori with triple therapy (metronidazole, tetracycline, and bismuth subsalicylate) during 1990 and 1991. Those who had frozen serum samples available from that time were contacted to have follow-up serum collected in 1994. A simultaneous [13C]urea breath test was done to confirm H pylori infection status. Serology was determined by quantitative enzyme-linked immunosorbent assay (ELISA) and qualitative immunoassay.
RESULTS: All 29 patients who agreed to participate were free of H pylori infection. They had a mean decrease in H pylori IgG titers of 51% from baseline (P <0.001). Titers remained stable from 1 year to a mean of 3.5 years after therapy (range 2.8 to 4.4). Of the 29 patients, 21 (72%) remained seropositive by ELISA 3.5 years after successful H pylori treatment, and 18 (62%) remained positive by rapid serum immunoassay.
CONCLUSION: IgG titers against H pylori plateau at a 50% decrease after therapy. Helicobacter pylori serology, either quantitative or qualitative, will yield false positive results in patients who have previously been treated for H pylori and should not be used to determine infection status in this population.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9688016     DOI: 10.1016/s0002-9343(98)00134-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  15 in total

1.  Stool Antigen Testing, a Reliable Noninvasive Method of Assessment of Helicobacter pylori Infection Among Patients with Gastro-duodenal Disorders in Cameroon.

Authors:  Laure Brigitte Kouitcheu Mabeku; Mohamadou Bello Epesse; Stephane Fotsing; Roland Kamgang; Magloire Tchidjo
Journal:  Dig Dis Sci       Date:  2020-04-30       Impact factor: 3.199

2.  Helicobacter pylori-negative gastritis: prevalence and risk factors.

Authors:  Helena Nordenstedt; David Y Graham; Jennifer R Kramer; Massimo Rugge; Gordana Verstovsek; Stephanie Fitzgerald; Abeer Alsarraj; Yasser Shaib; Maria E Velez; Neena Abraham; Bhupinderjit Anand; Rhonda Cole; Hashem B El-Serag
Journal:  Am J Gastroenterol       Date:  2012-11-13       Impact factor: 10.864

3.  Helicobacter pylori infection and prevalence of high blood pressure among Chinese adults.

Authors:  Zhengce Wan; Liu Hu; Mei Hu; Xiaomei Lei; Yuancheng Huang; Yongman Lv
Journal:  J Hum Hypertens       Date:  2017-12-30       Impact factor: 3.012

4.  Evaluation of two commercial enzyme immunoassays, testing immunoglobulin G (IgG) and IgA responses, for diagnosis of Helicobacter pylori infection in children.

Authors:  A Kindermann; N Konstantopoulos; N Lehn; H Demmelmair; S Koletzko
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

5.  Helicobacter pylori infection and typhoid fever in Jakarta, Indonesia.

Authors:  A M Vollaard; H W Verspaget; S Ali; L G Visser; R A Veenendaal; H A G H Van Asten; S Widjaja; Ch Surjadi; J T Van Dissel
Journal:  Epidemiol Infect       Date:  2006-02       Impact factor: 2.451

6.  Dynamics of Helicobacter pylori-specific immunoglobulin G for 2 years after successful eradication of Helicobacter pylori infection in an American Indian and Alaska Native population.

Authors:  Karen M Miernyk; Dana L Bruden; Michael G Bruce; Brian J McMahon; Thomas W Hennessy; Helen V Peters; Debby A Hurlburt; Frank Sacco; Alan J Parkinson
Journal:  Clin Vaccine Immunol       Date:  2006-11-01

7.  Serologic Evidence for Fecal-Oral Transmission of Helicobacter pylori.

Authors:  David Bui; Heidi E Brown; Robin B Harris; Eyal Oren
Journal:  Am J Trop Med Hyg       Date:  2015-11-23       Impact factor: 2.345

8.  Helicobacter pylori infection and the risk of Barrett's oesophagus: a community-based study.

Authors:  D A Corley; A Kubo; T R Levin; G Block; L Habel; W Zhao; P Leighton; G Rumore; C Quesenberry; P Buffler; J Parsonnet
Journal:  Gut       Date:  2007-09-25       Impact factor: 23.059

9.  Helicobacter pylori and gastroesophageal reflux disease: a case-control study.

Authors:  Douglas A Corley; Ai Kubo; T R Levin; Gladys Block; Laurel Habel; Gregory Rumore; Charles Quesenberry; Patricia Buffler; Julie Parsonnet
Journal:  Helicobacter       Date:  2008-10       Impact factor: 5.753

10.  Assessment of Helicobacter pylori eradication in patients on NSAID treatment.

Authors:  Harald E Vonkeman; Htji Deleest; Mafj van Delaar; J Vanbaarlen; Kss Steen; Wf Lems; Jwj Bijlsma; Ej Kuipers; Hhml Houben; M Janssen; Bac Dijkmans
Journal:  BMC Gastroenterol       Date:  2012-09-24       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.